Establishment Labs is a healthcare company specializing in innovative solutions for breast reconstruction and augmentation. Its core products include silicone breast implants and related medical devices. The company operates primarily in the aesthetic and reconstructive surgery segments, with major revenue sources stemming from sales of its implants and surgical products in various international markets.
The stock presents a neutral investment profile, appealing to investors seeking a balanced approach. It shows potential for growth, supported by recent revenue increases, but also carries inherent risks associated with its market position and financial performance. This makes it suitable for investors looking for a mix of stability and growth potential.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-26 | Hold | Sell | Weak fundamentals and negative momentum raise significant risk. |
| 2026-08-18 | — | Hold | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-07 | BTIG | Target Raised | 96 → 103 | 79.05 |
| 2026-08-06 | Needham | Target Raised | — → 95 | 79.05 |
| 2026-08-06 | Canaccord Genuity | Target Raised | — → 105 | 79.05 |
| 2026-07-15 | Mizuho Securities | Target Raised | 100 → 105 | 86.59 |
| 2025-12-31 | BTIG | Target Raised | — → 86 | 72.92 |
| 2025-12-17 | Canaccord Genuity | Target Raised | 72 → 85 | 74.15 |
| 2025-12-10 | Needham | Target Raised | — → 84 | 71.01 |
| 2025-11-14 | BTIG | Target Raised | — → 81 | 64.75 |
| 2025-11-06 | Needham | Target Raised | 48 → 70 | 64.91 |
| 2025-11-05 | BTIG | Target Raised | — → 70 | 59.55 |
